Qiagen to Acquire Bioanalytical Assets from SuNyx GmbH
News Aug 01, 2005
Qiagen N.V. has announced that it has entered into a definitive agreement to acquire the assets related to the bioanalytical business of SuNyx GmbH. SuNyx has developed and recently initiated marketing of its MPep and MProtChip® platforms for sample preparation of peptide and protein samples for analysis on Liquid Chromatography (LC)-MALDI Mass Spectrometry. According to the Company, these products allow examining dimensions in sample preparation by leveraging nanotechnology-based surface structures.
MALDI Mass Spectrometry has become the important analytical tool in the identification of proteins and evaluation of their role in biological processes in the areas of proteomics, drug discovery, and biomarker identification. A LC-MALDI protocol consists of sample purification, enzymatic digestion, and separation of peptides by LC and identification of proteins by peptide mass fingerprint.
The MPep and MProtChip® technology are designed to provide inherent confinement of defined volumes of sample drops resulting in precise fraction collection from the liquid chromatography run, even under high throughput conditions. The optimized pre-deposited matrix spot leads to an up to 100-fold increased sensitivity due to on-chip pre-concentration effects. SuNyx's MPep and MProtChip® platforms can be used on major MS instruments suitable for LC-MALDI.
The acquisition of the bioanalytical business of SuNyX expands on a previous licensing arrangement. Subject to the terms of the acquisition agreement, Qiagen will pay approximately US$0.8 million in cash in exchange for the relevant assets. An additional consideration of approximately US$0.8 million is subject to certain milestones. Qiagen anticipates that the transaction will add approximately US$1 million in net sales and will have a slightly dilutive impact of approximately US$0.5 million on Qiagen's net income in 2006 and will be accretive thereafter.
"The acquisitions of key assets of LumiCyte and of the bioanalytical assets of SuNyx position Qiagen as the leading provider for standardized, on-chip sample preparation in the rapidly growing field of MALDI and LC-MALDI Mass Spectrometry for protein analysis," said Peer M. Schatz, Qiagen's Chief Executive Officer.
"SuNyx products are highly complementary to LumiCyte's technology portfolio and complete Qiagen's solutions for application-specific sample preparation for MALDI-based protein identification and analysis. We are observing an increasing interest in the analysis of low abundant proteins, which seem to play significant roles in cell regulation processes. The ease of use and the nanotechnology-based, on-chip concentration features make SuNyx MALDI chips a perfect pre-analytical tool for high sensitivity LC-MALDI Mass Spectrometry."
"SuNyx has recently developed highly innovative products for use in the field of proteomics with their MPep and MProtChip® technology, which clearly addressed customer needs for cost-effective, convenient and reliable sample preparation and analysis tools in the area of MALDI MS," added Michael Lutz, Chief Executive Officer of SuNyx. "Teaming up with Qiagen, the world's leading provider of enabling technologies for pre-analytical sample preparation in life sciences will allow SuNyx to further grow its technology and explore additional value-adding opportunities."
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018